ARV-102 was well tolerated in clinical trials for both healthy volunteers and patients with Parkinson's disease - - ARV-102 demonstrated dose-dependent cerebrospinal fluid (CSF) exposure in subjects ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback